Hot Investor Mandate 1: Corporate VC Invests in Repurposed Drugs and New Combinations in CNS and Respiratory Diseases

Featured Posts

• Growth of An Early Stage Phenomenon: Four Years of RESI in Boston

  By Natasha Eldridge, RESI Conference Manager, LSN The first RESI event ever was held in Boston in 2013, with the goal of bringing the startups and the investors that LSN already worked with together for face to face meetings between parties who would be a good fit for each other’s business. From that seed, RESI has […]

• RESI San Diego: Family Office Investors Discuss Strategy and What Makes Them Different

  By Cole Bunn, Senior Research Analyst, LSN As the RESI San Diego event is now in the rearview mirror and we prepare to bring RESI home to Boston (Sept. 26th), we wanted to take a closer look at the Medtech Family Office panel session. Family offices are clearly a highly sought-after investor class and are […]

• Regulatory “Fast Tracking” Could Spell Opportunity for Innovators and Investors in Digital health

  By Michael Quigley, VP of Investor Research, LSN Earlier this year the FDA announced its plans to develop a Digital Health unit comprised of 13 engineers and experts in the digital health world, with the goal of restructuring the FDA’s assessment of digital health completely, making the process for approval more streamlined for new technologies. […]

• Hot Investor Mandate 1: Pharma Firm Creates Innovation Unit to Invest in New Solutions for Skin Diseases

  A pharma firm has created an independent R&D innovation unit to transform early stage innovations into solutions for improving the lives of people with skin disease; the unit is an agile group of scientific experts with an entrepreneurial mindset and a vision to enable precision medicine in Dermatology. The group looks to accelerate breakthrough research […]

• Hot Investor Mandate 2: European Life Science VC Invests in Early Stage Biotech and Devices

  A venture capital firm based in Europe that focuses solely on the life sciences is investing from their third fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. […]